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Interferon-g (IFN-g) is known primarily for its roles in
immunological responses but also has been shown to
affect fat metabolism and adipocyte gene expression. To
further investigate the effects of IFN-g on fat cells, we
examined the effects of this cytokine on the expression
of adipocyte transcription factors in 3T3-L1 adipocytes.
Although IFN-g regulated the expression of several adi-
pocyte transcription factors, IFN-g treatment resulted
in a rapid reduction of both peroxisome proliferator-
activated receptor (PPAR) protein and mRNA. A 48-h
exposure to IFN-g also resulted in a decrease of both
CCAAT/enhancer-binding a and sterol regulatory ele-
ment binding protein (SREBP-1) expression. The short
half-life of both the PPARg mRNA and protein likely
contributed to the rapid decline of both cytosolic and
nuclear PPARg in the presence of IFN-g. Our studies
clearly demonstrated that the IFN-g-induced loss of
PPARg protein is partially inhibited in the presence of
two distinct proteasome inhibitors. Moreover, IFN-g
also inhibited the transcription of PPARg, which was
accompanied by a decrease in PPARg mRNA accumula-
tion. In addition, exposure to IFN-g resulted in a sub-
stantial increase in STAT 1 expression and a small in-
crease in STAT 3 expression. IFN-g treatment of 3T3-L1
adipocytes (48–96 h) resulted in a substantial inhibition
of insulin-sensitive glucose uptake. These data clearly
demonstrate that IFN-g treatment results in the devel-
opment of insulin resistance, which is accompanied by
the regulation of various adipocyte transcription fac-
tors, in particular the synthesis and degradation of
PPARg.
The adipocyte plays an active role in a variety of physiolog-
ical and pathological processes regulating energy metabolism.
The recent consideration of adipose tissue as an endocrine
organ that secretes a variety of unrelated bioactive molecules
has broadened our understanding of adipocyte function to ex-
ceed its previously considered passive role in lipid metabolism.
A number of cell lines are available for studying adipocytes.
The 3T3-L1 cell line differentiates under the controlled condi-
tions of cell culture from fibroblasts, or preadipocytes, to cells
with the morphological and biochemical properties of adipo-
cytes (1, 2). The 3T3-L1 adipocytes are comparable with native
adipocytes as they have the ability to accumulate lipid, respond
to insulin, and secrete leptin. The major transcription factors
involved in adipocyte gene regulation include peroxisome pro-
liferator-activated receptor g, proteins belonging to the
CCAAT/enhancer-binding protein family, and adipocyte deter-
mination and differentiation-dependent factor 1, also known as
sterol regulatory element-binding protein (reviewed in Refs. 3
and 4).
Recent studies have also suggested that the signal trans-
ducer and activator of transcription (STAT)1 family of tran-
scription factors may also be important in fat cells. The STAT
family of transcription factors is comprised of seven family
members (STATs 1, 2, 3, 4, 5A, 5B, and 6) that, in response to
the stimulation of various receptors, mainly those for cyto-
kines, are phosphorylated on tyrosine residues, which causes
their translocation to the nucleus. Each STAT family member
shows a distinct pattern of activation by cytokines and upon
nuclear translocation can regulate the transcription of partic-
ular genes in a cell- or tissue-specific manner (5). In fat cells,
the expression of STATs 1, 5A, and 5B is highly induced during
differentiation and correlates with lipid accumulation (6, 7).
The regulation of STAT expression has also been investigated
in NIH 3T3 cells ectopically overexpressing C/EBPs b and d, a
condition that results in adipogenesis (8). In these studies, the
expression of STATs 1, 5A, and 5B was induced in a PPARg
ligand-dependent fashion during adipogenesis (9). STATs 3 and
6 are also expressed in adipocytes, but the expression of these
proteins does not change during differentiation. However, the
tyrosine phosphorylation of STAT 3 occurs following the induc-
tion of differentiation, and studies with antisense STAT 3 sug-
gest that this protein may be important in adipogenesis (10).
Although the functions of STATs in fat cells have not been
identified, numerous studies suggest that these transcription
factors may be important regulators of adipocyte gene
expression.
Interferon-g (IFN-g) is primarily known for its roles in im-
munological responses but also has been shown to affect fat
metabolism and adipocyte gene expression. In adipocytes,
IFN-g treatment results in a decrease of lipoprotein lipase
activity and increased lipolysis (11). In 3T3-F442 adipocytes,
exposure to IFN-g results in a decreased expression of lipopro-
tein lipase and fatty acid synthase. Also in various rodent
preadipocyte cell lines, IFN-g inhibits the differentiation of
preadipocytes (12–14). We have recently shown that acute
IFN-g treatment of cultured and native adipocytes results in a
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dose- and time-dependent activation of STATs 1 and 3 (15).
Exposure of adipocytes to IFN-g results in the tyrosine phos-
phorylation and nuclear translocation of STATs 1 and 3 in fat
cells. Because IFN-g has effects on adipocyte gene expression,
we examined the effects of this cytokine on the expression of a
variety of adipocyte transcription factors.
Although we observed that IFN-g affected the expression of
a number of adipocyte transcription factors, the most profound
effect of IFN-g was on the expression of PPARg. PPARg is a
member of the nuclear hormone superfamily and exists as two
isoforms, PPARg1 and PPARg2, which are transcribed from
the same gene by the use of alternative promoters (16).
PPARg2 is 30 amino acids longer than PPARg1 and is largely
adipocyte-specific. Although expressed in a variety of other
tissues, PPARg1 is also predominately expressed in fat (17).
Thiazolidinediones (TZDs) are high affinity synthetic ligands of
PPARg and have recently been shown to affect the degradation
of this transcription factor (18). Our studies with IFN-g also
indicate that PPARg is targeted to the proteasome for degra-
dation, but this is not the only mechanism for the substantial
effect that IFN-g has on PPARg expression. Our findings indi-
cate that a newly identified inhibitor of PPARg expression,
IFN-g, results in a substantial loss of PPARg expression by
regulating two cellular events as follows: 1) targeting PPARg to
the proteasome for degradation and 2) inhibiting the synthesis
of PPARg. Prolonged IFN-g treatment of 3T3-L1 adipocytes
also results in the development of insulin resistance and reg-
ulation of other adipocyte transcription factors and supports
the hypothesis that PPARg is involved in conferring insulin
sensitivity.
EXPERIMENTAL PROCEDURES
Materials—Dulbecco’s modified Eagle’s medium (DMEM) was pur-
chased from Life Technologies, Inc. Bovine and fetal bovine serum was
obtained from Sigma and Life Technologies, Inc., respectively. Murine
interferon-g (IFN-g) was purchased from Roche Molecular Biochemi-
cals. Actinomycin D was purchased from Calbiochem. Cycloheximide
was purchased from Sigma. The nonphospho STAT antibodies were
either monoclonal IgGs purchased from Transduction Laboratories or
polyclonal IgGs from Santa Cruz Biotechnology Inc. A highly phospho-
specific polyclonal antibody for STAT 1 (Y701) was provided by Quality
Controlled Biochemicals. PPARg was a mouse monoclonal antibody
from Santa Cruz Biotechnology Inc. SREBP-1, C/EBPa, and ERK1/
ERK2 were rabbit polyclonal antibodies from Santa Cruz Biotechnology
Inc.
Cell Culture—Murine 3T3-L1 preadipocytes were plated and grown
to 2 days postconfluence in DMEM with 10% bovine serum. Medium
was changed every 48 h. Cells were induced to differentiate by changing
the medium to DMEM containing 10% fetal bovine serum, 0.5 mM
3-isobutyl-1-methylxanthine, 1 mM dexamethasone, and 1.7 mM insulin.
After 48 h this medium was replaced with DMEM supplemented with
10% fetal bovine serum, and cells were maintained in this medium until
utilized for experimentation.
Preparation of Whole Cell Extracts—Monolayers of 3T3-L1 adipo-
cytes were rinsed with phosphate-buffered saline and then harvested in
a nondenaturing buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1
mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, 1 mM pepstatin, 50 trypsin inhibitory
milliunits of aprotinin, 10 mM leupeptin, and 2 mM sodium vanadate.
Samples were extracted for 30 min on ice and centrifuged at 15,000 rpm
at 4 °C for 15 min. Supernatants containing whole cell extracts were
analyzed for protein content using a BCA kit (Pierce) according to the
manufacturer’s instructions.
Preparation of Nuclear/Cytosolic Extracts—Cell monolayers were
rinsed with phosphate-buffered saline and then harvested in a nuclear
homogenization buffer (NHB) containing 20 mM Tris (pH 7.4), 10 mM
NaCl, and 3 mM MgCl2. Nonidet P-40 was added to a final concentration
of 0.15%, and cells were homogenized with 16 strokes in a Dounce
homogenizer. The homogenates were centrifuged at 1500 rpm for 5 min.
Supernatants were saved as cytosolic extract, and the nuclear pellets
were resuspended in 0.5 volume of NHB and centrifuged as before. The
pellet of intact nuclei was resuspended again in 0.5 of the original
volume of NHB and centrifuged again. A small portion of the nuclei was
used for trypan blue staining to examine the integrity of the nuclei. The
majority of the pellet (intact nuclei) was resuspended in an extraction
buffer containing 20 mM HEPES (pH 7.9), 420 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, and 25% glycerol. Nuclei were extracted for 30 min on ice
and then placed at room temperature for 10 min. Two hundred units of
DNase I were added to each sample, and tubes were inverted and
incubated an additional 10 min at room temperature. Finally, the
sample was subjected to centrifugation at 15,000 rpm at 4 °C for 30 min.
Supernatants containing nuclear extracts were analyzed for protein
content.
Gel Electrophoresis and Immunoblotting—Proteins were separated
in 5, 7.5, or 12% polyacrylamide (acrylamide from National Diagnostics)
gels containing sodium dodecyl sulfate (SDS) according to Laemmli (19)
and transferred to nitrocellulose (Bio-Rad) in 25 mM Tris, 192 mM
glycine, and 20% methanol. Following the transfer, the membrane was
blocked in 4% milk for 1 h at room temperature. Results were visualized
with horseradish peroxidase-conjugated secondary antibodies (Sigma)
and enhanced chemiluminescence (Pierce).
RNA Analysis—Total RNA was isolated from cell monolayers with
TriZOL (Life Technologies, Inc.) according to the manufacturer’s in-
struction with minor modifications. For Northern blot analysis, 20 mg of
total RNA was denatured in formamide and electrophoresed through a
formaldehyde-agarose gel. The RNA was transferred to Zeta Probe-GT
(Bio-Rad), cross-linked, hybridized, and washed as previously described
(20). Probes were labeled by random priming using the Klenow frag-
ment (Promega) and [a-32P]dATP (PerkinElmer Life Sciences).
Determination of 2-Deoxyglucose—The assay of 2-[3H]deoxyglucose
was performed as previously described (21). Prior to the assay, fully
differentiated 3T3-L1 adipocytes were serum-deprived for 2–4 h. Up-
take measurements were performed in triplicate under conditions
where hexose uptake was linear, and the results were corrected for
nonspecific uptake and absorption determined by 2-[3H]deoxyglucose
uptake in the presence of 5 mM cytochalasin B (Sigma). Nonspecific
uptake and absorption were always less than 10% of the total uptake.
Nuclei Isolation and Run-on Transcription Assays—Following expo-
sure of fully differentiated adipocytes to IFN-g for 1 h, the cell mono-
layers (six 10-cm plates per time point) were washed once with ice-cold
phosphate-buffered saline and nuclei were isolated, and run-on tran-
scription assays were performed as we have previously described (20).
RESULTS
The expression of adipocyte transcription factors was exam-
ined following a time course of IFN-g treatment on fully differ-
entiated 3T3-L1 adipocytes. As shown in Fig. 1, immunoblot-
ting of whole cell extracts demonstrated that IFN-g treatment
resulted in a significant decrease in PPARg2 (upper band) and
-g1(lower band) within 24 h and resulted in a notable decline in
C/EBPa. The expression of STATs 1 and 3 increased following
a 24-h IFN-g treatment. The expression of STATs 5A, 5B, and
6 was not regulated by exposure to IFN-g treatment. Also, the
expression of SREBP-1 decreased after a 48-h treatment. The
spliced 67-kDa form of SREBP-1 was similarly decreased with
IFN-g treatment (data not shown).
As shown in Fig. 1, a 24-h treatment of IFN-g resulted in a
substantial loss of PPARg2 and -g1 protein expression. There-
fore, we examined the effects of IFN-g over a 24-h time course.
Whole cell extracts were isolated from fully differentiated
3T3-L1 adipocytes that were treated with IFN-g for the various
times indicated in Fig. 2. Interestingly, IFN-g resulted in a
substantial loss of PPARg2 and -g1 expression within 6 h. In
addition, we observed a striking increase in STAT 1 expression
between 8 and 12 h and a small increase in STAT 3 during this
time period. There was no change in STAT 5A during this time
course. JAK 1, the kinase that activates STAT 1 in adipocytes,
increases slightly with IFN-g treatment. In addition, fatty acid
synthase expression decreased with IFN-g treatment.
Clearly, an analysis of whole cell extracts reveals a substan-
tial loss of PPARg2 and -g1 expression in adipocytes following
IFN-g treatment. However, it was unclear whether IFN-g had
any effect on the amount of PPARg proteins present in the
adipocyte nucleus. To further examine the inhibition of PPARg
by IFN-g, we performed another time course in which adipo-
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cytes were fractionated to isolate cytosolic and nuclear ex-
tracts. As shown in the top panel of Fig. 3, the majority of
PPARg2 and -g1 protein was present in the nucleus, and the
amount of nuclear PPARg protein was substantially reduced
after 6 h. A darker exposure of this blot indicates the presence
of PPARg proteins in the cytosol in untreated adipocytes and
cells that were exposed to IFN-g for 30 min. However, following
a 6-h or greater IFN-g treatment, there was no detectable
PPARg2 or -g1 in the cytosol and a significant loss of both
PPARg isoforms in the nucleus. We also observed an increase
in STAT 1 in the cytosol between 6 and 12 h and the presence
of activated STAT 1 in the nucleus following a 30-min treat-
ment with IFN-g. Detection of the phosphorylated form of
STAT 1 was performed with an antibody specific for phospho-
rylation on tyrosine 701 (STAT 1 Y701). Analysis with either
one of these STAT 1 antibodies demonstrates the presence of
STAT 1 in the nucleus following a 30-min IFN-g stimulation.
However, the STAT 1 Y701 antibody is more sensitive, and we
observed this protein in the nucleus even after a 12-h IFN-g
treatment. We have previously reported that STAT 5A is pres-
ent in the nucleus of adipocytes under basal conditions (15),
and IFN-g treatment does not cause a redistribution of this
protein. Therefore, STAT 5A (Fig. 3, bottom panel) is shown to
indicate the even loading of both cytosolic and nuclear samples.
The rapid loss of PPARg1 and -g2 proteins in the presence of
IFN-g suggested that the PPARg proteins may be labile. There-
fore, we examined the decay of PPARg and STATs in 3T3-L1
adipocytes. Whole cell extracts were isolated from 3T3-L1 adi-
pocytes at various times following the addition of 5 mM cyclo-
heximide (1CH) or ethanol (2CH), a vehicle control. As shown
in Fig. 4, the inhibition of protein synthesis resulted in the loss
of PPARg by 12 h with over half of the protein decayed by 6 h.
A log plot of the remaining protein versus time was used to
estimate the half-life of PPARg and of adipocyte-expressed
STAT proteins. The estimated half-life of these proteins is
indicated in Fig. 4 and is an average calculation of three inde-
FIG. 1. The effects of IFN-g on the expression of adipocyte
transcription factors. Whole cell extracts were prepared from fully
differentiated 3T3-L1 adipocytes following a treatment with 100
units/ml IFN-g for 0, 24, 48, 72, or 96 h. Cells were treated every 24 h
with a fresh bolus of IFN-g. Extracts were prepared as described under
“Experimental Procedures.” One hundred mg of each extract was sepa-
rated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. The molecular mass of each protein is indicated
to the left of the blot in kilodaltons. The detection system was horse-
radish peroxidase-conjugated secondary antibodies (Sigma) and en-
hanced chemiluminescence (Pierce). This is a representative experi-
ment independently performed three times.
FIG. 2. IFN-g treatment results in a rapid loss of PPARg ex-
pression in adipocytes. Whole cell extracts were prepared from fully
differentiated 3T3-L1 adipocytes following a treatment with 100
units/ml IFN-g as indicated at the top of the figure. One hundred mg of
each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. The molecular mass of each
protein is indicated to the left of the blot in kilodaltons. Samples were
processed and results were visualized as described in the legend to Fig.
1. This is a representative experiment independently performed three
times. (JAK1, the kinase that activates STAT1 in adipocytes.
FIG. 3. IFN-g treatment results in a decrease of nuclear PPARg
and an increase in cytosolic STAT 1 in adipocytes. Cytosolic and
nuclear extracts were isolated from fully differentiated 3T3-L1 adipo-
cytes following treatment with IFN-g as indicated at the top of the
figure. One hundred mg of each extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.
Samples were processed and results were visualized as described in the
legend to Fig. 1. This is a representative experiment independently
performed two times.
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pendent experiments. PPARg1 and -g2 are labile compared
with the STAT proteins, which have half-lives at least twice as
long as the PPARg proteins. We also investigated the effect of
IFN-g on PPARg in the presence of cycloheximide. Because of
experimental variability, it was difficult to quantitate the de-
crease in the half-life of the PPARg proteins in the presence of
IFN-g. However, in each experiment, the decay of the PPARg
was quicker in the presence of IFN-g, as shown in Fig. 5.
Adipocytes were treated with 5 mM cycloheximide in the pres-
ence or absence of IFN-g, and whole cell extracts were isolated
at 0, 1, and 4 h. As shown in Fig. 5, the decay of both PPARg2
and -g1 is increased in the presence of IFN-g with a complete
loss of PPARg1 at 4 h.
TZD treatment has also been shown to decrease PPARg
expression. Therefore, we compared the effects of IFN-g and
englitazone (ENG), a TZD, on the expression of PPARg in
adipocytes. As shown in Fig. 6, fully differentiated adipocytes
were exposed to IFN-g or ENG alone or in combination. In the
first combination, adipocytes were treated with IFN-g 1 h prior
to the addition of englitazone. In the second combination, adi-
pocytes were treated with englitazone 1 h prior to the addition
of IFN-g. For each combination, whole cell extracts were iso-
lated 5 h after initiation of the experiment. These results dem-
onstrate that the combination of both inhibitors of PPARg
expression resulted in an even greater decrease in PPARg
expression than one agonist alone.
The results of the cycloheximide experiments in Fig. 5 sug-
gest that the decay of PPARg2 and -g1 is increased in the
presence of IFN-g. Therefore, we examined PPARg expression
in the presence of proteasome inhibitors. As shown in Fig. 7, a
6-h treatment of either epoxomicin or lactacystin had little
effect on the levels of PPARg2 or -g1 protein. A 6-h IFN-g
treatment resulted in a substantial loss of PPARg protein, but
the IFN-g-induced loss of PPARg2 and -g1 was inhibited in the
presence of either epoxomicin or lactacystin. Notably, the pres-
ence of these two different proteasome inhibitors did not re-
store PPARg2 and -g1 to the levels found in untreated adipo-
cytes, suggesting that protein degradation is only one manner
in which IFN-g regulates PPARg expression. In the presence of
the two proteasome inhibitors, there were no differences in the
levels of any STATs or ERK1/ERK2. Interestingly, the IFN-g-
induced increase in STAT 1 was blunted in the presence of
epoxomicin or lactacystin, suggesting that the IFN-g-induced
increase in STAT 1 may be dependent on the degradation of
some protein(s).
These experiments indicate that, in addition to having an
effect on the turnover of the PPARg proteins, there is presum-
ably another means by which IFN-g causes a decrease in
PPARg expression. Therefore, we examined the effect of IFN-g
on PPARg mRNA accumulation. As shown in Fig. 8, a 2-h
IFN-g treatment resulted in a substantial loss of PPARg
mRNA. Northern blot analysis cannot distinguish between the
two forms of PPARg. A decrease in C/EBPa and GLUT4 was
also observed following a 20-h IFN-g treatment. In addition, we
observed an increase in the levels of both C/EBPb and C/EBPd
following an IFN-g treatment. A notable decrease in aP2/422
was observed after a 12-h treatment with IFN-g. The expres-
sion of glycerol phosphate dehydrogenase (GPD), a gene whose
expression is elevated in adipocytes, was substantially de-
creased following a 20-h treatment with IFN-g. Following a
24-h IFN-g treatment, there was also a slight decline in adipsin
mRNA. The hybridization of b-actin is shown to represent the
even loading of the samples.
Because the IFN-g-induced loss of PPARg mRNA was rela-
tively rapid, we predicted that the decay of the PPARg mRNA
FIG. 4. The turnover of PPARg and adipocyte-expressed STAT
proteins. Whole cell extracts were prepared from 3T3-L1 adipocytes
following various periods of treatment with 5 mM cycloheximide (1CH)
or ethanol (2CH), a vehicle control. One hundred mg of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. Samples were processed and results were visu-
alized as described in the legend to Fig. 1. This is a representative
experiment independently performed three times.
FIG. 5. PPARg turnover is increased in the presence of IFN-g.
Whole cell extracts were prepared from 3T3-L1 adipocytes following
various periods of treatment with 5 mM cycloheximide or ethanol in the
presence or absence of IFN-g. One hundred mg of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to
Western blot analysis. Samples were processed and results were visu-
alized as described in the legend to Fig. 1. This is a representative
experiment independently performed three times.
FIG. 6. The IFN-g-induced increase of PPARg expression is
even greater in the presence of englitazone. Whole cell extracts
were prepared from fully differentiated 3T3-L1 adipocytes following a
5-h treatment of IFN-g, ENG, IFN-g 1 ENG (added 1 h after the
addition of IFN-g), and ENG 1 IFN-g (added 1 h after the addition of
ENG). One hundred mg of each extract was separated by SDS-PAGE,
transferred to nitrocellulose, and subjected to Western blot analysis.
Samples were processed and results were visualized as described in the
legend to Fig. 1. CTL, control.
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would be brief compared with C/EBPa. Therefore, we investi-
gated the turnover of these two transcription factor mRNAs.
Total RNA was isolated from cells at various times after treat-
ment with actinomycin D. As shown in Fig. 9A, the PPARg
mRNA decayed rapidly compared with the C/EBPa mRNA. We
estimated the half-life of the PPARg mRNA to be less than 3 h.
We also examined the decay of PPARg in the presence of IFN-g
to determine whether this growth factor had any effect on the
stability of the PPARg mRNA. We found that the decay of
PPARg mRNA was not altered in the presence of IFN-g as
indicated in Fig. 9B. These results strongly suggested that
IFN-g would have an effect on the transcription of PPARg.
To determine whether the IFN-g-induced changes in PPARg
and C/EBPa mRNA accumulation shown in Fig. 8 were attrib-
utable to the effects on synthesis, we measured the transcrip-
tion rates of these genes in nuclei isolated from control and
IFN-g-treated adipocytes. Fully differentiated 3T3-L1 adipo-
cytes were exposed to cycloheximide (6IFN-g) for 1 h. As shown
in Fig. 10, a substantial suppression of both PPARg and
C/EBPa was observed following IFN-g treatment, indicating
that the effect of IFN-g on the transcription of these genes was
independent of new protein synthesis. IFN-g had no effect on
b-actin transcription (data not shown).
IFN-g is known to have effects on both lipolysis and lipogen-
esis, so we investigated the effect of this growth factor on basal
and insulin-sensitive glucose uptake. As shown in Table I,
serum-deprived 3T3-L1 adipocytes had a 6.7-fold increase in
glucose uptake following a 10-min treatment of 100 nM insulin.
After a 24-h treatment of IFN-g, cultured adipocytes were still
responsive to insulin (6.13-fold increase). However, following a
48-h treatment of IFN-g, when both PPARg and C/EBPa were
substantially decreased (Fig. 1), there was a discernible de-
crease in insulin-stimulated glucose uptake (4.42-fold in-
crease). Exposure to IFN-g for 72 and 96 h had no effect on
basal glucose uptake but resulted in a substantial decrease in
insulin-sensitive glucose uptake. Following a 96-h IFN-g expo-
sure, there was only a 2.2-fold increase following insulin treat-
ment. IFN-g treatment for more than 96 h did not result in a
further decline of insulin-sensitive glucose uptake (data not
shown). The IFN-g-induced effects on insulin sensitivity do not
appear to be a result of any significant lipid loss as there were
no distinguishable differences in Oil Red O staining from con-
trol and IFN-g-treated (96 h) adipocytes (data not shown).
DISCUSSION
IFN-g affected the expression of many adipocyte transcrip-
tion factors, including PPARg2 and -g1, C/EBPa, C/EBPb,
C/EBPd, SREBP-1, STAT 1, and STAT 3. However, the most
profound effect of IFN-g was on PPARg expression. These
studies have also revealed that both the PPARg mRNA and
protein are labile compared with other adipocyte transcription
factors. IFN-g treatment of adipocytes leads to a decrease in
PPARg that is the result of the inhibition of transcription
coupled with an increase in the degradation of PPARg2 and
-g1. Interestingly, recent studies have revealed that thiazo-
lidinedione treatment of the 3T3-F442A adipocytes results in a
reduction of PPARg protein that is distinct from mRNA regu-
lation (18). In that study, the data indicated that the TZD
treatment of adipocytes resulted in the ubiquitination of
PPARg and subsequent degradation that was dependent on the
proteasome complex (18). These results are comparable with
the effects we observed with IFN-g. In our studies, two distinct
FIG. 7. The IFN-g-induced decrease of PPARg is partially in-
hibited in the presence of proteasome inhibitors. Whole cell ex-
tracts were prepared from fully differentiated 3T3-L1 adipocytes fol-
lowing a 6-h treatment of either 100 nM epoxomicin or 5 mM lactacystin
in the presence or absence of IFN-g (100 units/ml). One hundred mg of
each extract was separated by SDS-PAGE, transferred to nitrocellulose,
and subjected to Western blot analysis. Samples were processed and
results were visualized as described in the legend to Fig. 1. This is a
representative experiment independently performed three times. CTL,
control. FIG. 8. IFN-g treatment results in a rapid loss of PPARg mRNAand a decrease in expression of other adipocyte markers. Total
RNA was isolated from fully differentiated 3T3-L1 adipocytes following
treatment with IFN-g as indicated at the top of the figure. Twenty mg of
total RNA was electrophoresed, transferred to nylon, and subjected to
Northern blot analysis. This is a representative experiment independ-
ently performed two times. GPD, glycerol phosphate dehydrogenase.
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proteasome inhibitors affected PPARg2 and -g1 protein levels
in the presence of IFN-g but had little effect in adipocytes
lacking cytokine stimulation. In summary, both TZD and
IFN-g treatments of adipocytes appear to target PPARg to the
proteasome for degradation. Moreover, our observations on the
lability of PPARg proteins suggest that PPARg turnover is an
important event.
The inhibition of proteasome activity in the presence of
IFN-g did not restore the PPARg proteins to normal cellular
levels, and we observed a potent effect of IFN-g on PPARg
transcription and mRNA accumulation. These results have led
us to hypothesize that IFN-g-induced STAT 1 activation in fat
cells may be responsible for the transcriptional suppression of
PPARg. Cross-talk between STATs and PPARs has been dem-
onstrated in liver cells (22). We are currently initiating studies
to identify the IFN-g-sensitive element in the PPARg promot-
ers and determine whether STAT 1 is directly involved in the
transcriptional suppression of PPARg. Although STATs are
generally thought to be transcriptional activators, there is ev-
idence that this family of transcription factors can also act as
repressors of transcription (23). These studies have led us to
hypothesize that IFN-g-induced STAT 1 dimers directly bind
to the PPARg promoters and result in an inhibition of
transcription.
The effects of IFN-g on PPARg degradation are less expected.
Numerous studies have shown that serine phosphorylation of
PPARg on Ser112 by mitogen-activated protein kinases (ERK1/
ERK2 and stress-activated protein kinase/c-Jun NH2-terminal
FIG. 10. IFN-g treatment results in a suppression of PPARg
and C/EBPa transcription in adipocytes in a manner that is
independent of new protein synthesis. Nuclei were isolated from
fully differentiated adipocytes that were exposed to 5 mM cycloheximide
in the presence or absence of IFN-g for 1 h. Nuclei were subjected to
run-on analysis, and the autoradiogram displayed isa representative of
an experiment performed twice with independent preparations of nu-
clei. CTL, control.
TABLE I
The effect of IFN-g on insulin-sensitive glucose transport
Basal Insulin-stimulated -Foldincrease
pmol/min/mg protein
Control 67 6 12 449 6 38 6.70
24-h IFN-g 64 6 4 392 6 40 6.13
48-h IFN-g 66 6 10 292 6 28 4.42
72-h IFN-g 56 6 6 212 6 20 3.80
96-h IFN-g 53 6 8 117 6 13 2.20
FIG. 9. PPARg mRNA is more labile
than C/EBPa mRNA in adipocytes,
and the decay of these mRNAs is not
affected by IFN-g. A, total RNA was
isolated from fully differentiated 3T3-L1
adipocytes following treatment with 5
mg/ml actinomycin D for the various peri-
ods of time indicated at the top of the
figure. Control samples (2actinomycin D)
were isolated at the start and finish of the
experiment. B, total RNA was isolated
from fully differentiated 3T3-L1 adipo-
cytes following treatment with 5 mg/ml
actinomycin D for the various periods of
time indicated at the top of the figure in
the absence or presence of IFN-g. In each
experiment, 20 mg of total RNA was elec-
trophoresed, transferred to nylon, and
subjected to Northern blot analysis for
C/EBPa and PPARg. This is a represent-
ative experiment independently per-
formed two times.
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kinase) results in a strong suppression of PPARg activity (24–
27), which in part appears to involve ligand binding (28). Our
previous studies in the 3T3-L1 adipocytes have demonstrated
that IFN-g resulted in both STAT 1 and STAT 3 tyrosine
phosphorylation and nuclear translocation (15). However, un-
like other cytokines, IFN-g did not result in the activation of
ERK1/ERK2 in adipocytes. Therefore, it does not appear that
ERK1/ERK2-induced serine phosphorylation of PPARg could
be involved in the effects of IFN-g that we observed on PPARg
degradation. Our results are supported by the findings of
Spiegelman and co-workers (18), which indicate that the phos-
phorylation of PPARg on Ser112 is not required for its down-
regulation. However, we have not examined the role of serine
phosphorylation in the IFN-g-induced PPARg degradation or
the effect of IFN-g on the activation of c-Jun NH2-terminal
kinase in adipocytes.
Although the mechanism by which IFN-g directs PPARg to
the proteasome for degradation is not known, it is clear that the
turnover of PPARg is further increased when both IFN-g and a
PPARg ligand are present. Perhaps IFN-g could either modu-
late the phosphorylation state of PPARg or have an effect on
the synthesis of an endogenous PPARg ligand. Alternatively,
IFN-g-induced PPARg degradation could occur via a pathway
that is independent of ligand-induced degradation. It is inter-
esting to note that the analysis of PPARg mutants by the
Spiegelman laboratory demonstrated that the TZD-induced
PPARg decay was not strictly dependent on its transcriptional
activity but was dependent upon the ligand-gated activation
function (AF-2) domain. In these studies, ligand binding and
the activation of the AF-2 domain not only increased the tran-
scriptional function of PPARg but also induced ubiquitination
and subsequent proteasomal degradation.
Unlike TZDs, which are insulin sensitizers, IFN-g treatment
of adipocytes resulted in a condition of insulin resistance, as
measured by insulin-sensitive glucose uptake and a decrease in
the expression of adipocyte genes, such as GLUT4, aP2/422,
GPD, and adipsin. PPARg has been implicated in the regula-
tion of systemic insulin sensitivity, and some PPARg mutations
are associated with severe insulin resistance and diabetes mel-
litus (29). In our studies, the most profound effect of IFN-g was
on PPARg expression, which was significantly decreased after
only 6 h. Interestingly, we did not observe any substantial
effects on insulin-sensitive glucose uptake even after a 24-h
treatment of IFN-g despite the dramatic loss of PPARg expres-
sion. Following a 48-h treatment, we did observe a substantial
inhibition of insulin-sensitive glucose uptake. At this time,
there was also a marked effect on C/EBPa expression. These
studies suggest that the loss of PPARg may be insufficient to
confer insulin resistance in 3T3-L1 adipocytes. However, the
low levels of PPARg observed after a 24- and 48-h IFN-g treat-
ment may be sufficient levels of PPARg expression to account
for the insulin responsiveness of these cells. Alternatively, the
primary role of PPARg may be to regulate the expression of
other transcription factors, such as C/EBPa. Nonetheless, the
increase in PPARg turnover and the inhibition of PPARg syn-
thesis induced by IFN-g are prominent because of the relatively
rapid decay of both the PPARg mRNA and the protein. Because
the regulation of PPARg is the first observed effect of IFN-g on
adipocyte transcription factor expression, this event is likely
very important in the development of IFN-g-induced insulin
resistance. IFN-g treatment also results in a decrease of
GLUT4, aP2, GPD, and adipsin expression in adipocytes. How-
ever, there is no notable difference in the morphology of the
cells, and there is no observable difference in Oil Red O stain-
ing from untreated 3T3-L1 fully differentiated adipocytes and
those that have been treated for 96 h with IFN-g (data not
shown). In conclusion, the tightly controlled regulation of
PPARg synthesis and degradation that we observed in the
presence of IFN-g suggests that the cellular levels of PPARg
are a meaningful effector of gene expression.
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